Stratagene Launches ArrayAssist(R) CopyNumber; Only Guided Workflow Available to Biologists for Copy Number Analysis; Entire Ar
August 24 2006 - 6:30AM
Business Wire
Stratagene Corporation (NASDAQ:STGN), a leading developer,
manufacturer and marketer of specialized life science research and
diagnostic products, today announced the launch of its
ArrayAssist(R) Copy Number Software. This powerful yet extremely
intuitive software is the only guided workflow presently available
for copy number analysis, enabling researchers to easily manipulate
and analyze the massive data sets generated by leading chromosomal
copy number microarrays. The ArrayAssist Copy Number software is
Stratagene's most recent application on the ArrayAssist platform,
which includes ArrayAssist(R) Expression and ArrayAssist(R) Exon,
the latest versions of which were introduced in January 2006. All
ArrayAssist applications have earned GeneChip-compatible(TM) status
with the Affymetrix platform. They will soon be provided as
universal binaries, able to run natively on the latest Intel-based
Macintosh(R) computers, and are compatible with Mac(R) OS X,
Windows(R), and Linux(R). "Our ArrayAssist platform is deliberately
designed to make sophisticated, high-density array analysis
accessible to the life scientist," said David Edwards, Director,
Software Solutions at Stratagene. "The most current microarrays for
exon, copy number and expression analysis generate data sets that
break most traditional analytical tools. With a full spectrum of
advanced analytical features and dynamic interactive
visualizations, Stratagene's intuitive, easy-to-use ArrayAssist
platform helps biologists and biostatisticians conduct independent
advanced microarray data analysis." ArrayAssist Copy Number
supports the identification of biomarkers for cancer, degenerative
disease and developmental disorders by highlighting chromosomal
amplifications and deletions. Biologists can compare their
experimental data in ArrayAssist CopyNumber with a reference genome
using ArrayAssist's integrated genome browser, a feature of all
ArrayAssist applications, and map biological pathways for a
comprehensive understanding of the relevant relationships in their
system with the integration of Stratagene's PathwayArchitect(TM)
platform. Stratagene will be demonstrating ArrayAssist Copy Number
in Booth #6 at the Cambridge HealthTech Institute's Microarray Data
Analysis and Interpretation conference, being held at the
Ritz-Carlton in Washington D.C., from August 23 to 25, 2006.
Stratagene's ArrayAssist and PathwayArchitect products suites are
powered by the award-winning avadis(TM) technology and are
co-developed with Strand Life Sciences. About ArrayAssist The
ArrayAssist product suite provides easy to use, biology-focused
workflows designed to process a wide variety of gene expression
arrays, from raw .CEL data through primary expression and quality
analysis to advanced gene-level and exon-level analysis. It has a
comprehensive suite of tools to examine both transcriptional and
splicing regulation using the Affymetrix GeneChip arrays as well as
advanced analytical features such as multi-way ANOVA,
non-parametric statistical tests, classifiers for machine
learning-based prediction and sophisticated, interactive
visualization options. The ArrayAssist Expression, ArrayAssist
Exon, and ArrayAssist Copy Number products are fully integrated
with Stratagene's PathwayArchitect systems biology pathway analysis
software. About Stratagene Corporation Stratagene is a developer,
manufacturer and marketer of specialized life science research and
diagnostic products. The Company's life science research unit
supports advances in science by inventing, manufacturing and
distributing products that simplify, accelerate and improve
research. These products are used throughout the academic,
industrial and government research sectors in fields spanning
molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis, and high quality automated instrument and
reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as
well as its experience with FDA regulatory procedures, the Company
is pursuing opportunities to expand its product portfolio to
include molecular diagnostic kits and instrumentation. More
information is available at http://www.stratagene.com. Safe Harbor
Statement Certain statements in this news release that are not
historical fact constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Stockholders and other readers are cautioned not to place undue
reliance on these forward-looking statements. Stratagene generally
identifies forward-looking statements by using words like
"believe," "intend," "target," "expect," "estimate," "may,"
"should," "plan," "project," "contemplate," "anticipate," "predict"
or similar expressions. You can also identify forward-looking
statements by discussions of strategies, plans or intentions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, which may cause the actual results
of Stratagene to be materially different from historical results or
from any results expressed or implied by such forward-looking
statements. Among the important factors that could cause actual
results to differ materially from those contained in or implied by
the forward-looking statements are risks associated with the
company's inability to sufficiently anticipate market needs and
develop products and product enhancements that achieve market
acceptance, including molecular diagnostic testing kits and related
products, the company's ability to compete effectively in the
diagnostics and life sciences research markets, variability of the
company's quarterly revenues and operating results, the failure of
the company to retain key employees, the company's ability to
obtain additional debt or equity financing, the possibility of
declining sales due in part to a reduction in research and
development budgets or government funding, the company's ongoing
ability to protect its own intellectual property rights and to
avoid violating the intellectual property rights of third parties,
extended manufacturing difficulties and currency fluctuations. For
more information about these and other factors that could cause
actual results to differ materially from those contained in or
implied by the forward-looking statements please see "Factors that
May Affect Future Results" included in Stratagene's Annual Report
on Form 10-K for the year ended December 31, 2004 and in other
reports filed by Stratagene from time to time with the Securities
and Exchange Commission, including Quarterly Reports on Form 10-Q.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From May 2024 to Jun 2024
Stratagene (NASDAQ:STGN)
Historical Stock Chart
From Jun 2023 to Jun 2024